KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - AccuredRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arbutus Biopharma (ABUS) Total Liabilities (2016 - 2025)

Arbutus Biopharma (ABUS) has disclosed Total Liabilities for 16 consecutive years, with $18.0 million as the latest value for Q4 2025.

  • Quarterly Total Liabilities fell 47.46% to $18.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $18.0 million through Dec 2025, down 47.46% year-over-year, with the annual reading at $18.0 million for FY2025, 47.46% down from the prior year.
  • Total Liabilities hit $18.0 million in Q4 2025 for Arbutus Biopharma, down from $20.3 million in the prior quarter.
  • In the past five years, Total Liabilities ranged from a high of $71.0 million in Q1 2022 to a low of $18.0 million in Q4 2025.
  • Historically, Total Liabilities has averaged $39.6 million across 5 years, with a median of $36.6 million in 2024.
  • Biggest five-year swings in Total Liabilities: surged 121.35% in 2022 and later tumbled 47.46% in 2025.
  • Year by year, Total Liabilities stood at $35.0 million in 2021, then soared by 67.11% to $58.6 million in 2022, then plummeted by 34.46% to $38.4 million in 2023, then dropped by 10.53% to $34.3 million in 2024, then crashed by 47.46% to $18.0 million in 2025.
  • Business Quant data shows Total Liabilities for ABUS at $18.0 million in Q4 2025, $20.3 million in Q3 2025, and $20.3 million in Q2 2025.